Laurel Wealth Advisors (California)’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-14,490
Closed -$481K 351
2017
Q2
$481K Sell
14,490
-1,245
-8% -$38.5K 0.17% 155
2017
Q1
$504K Sell
15,735
-2,876
-15% -$98.1K 0.19% 132
2016
Q4
$674K Sell
18,611
-5,957
-24% -$238K 0.3% 96
2016
Q3
$1.13M Sell
24,568
-65
-0.3% -$3.39K 0.53% 58
2016
Q2
$1.24M Buy
24,633
+3,368
+16% +$179K 0.59% 43
2016
Q1
$1.14M Buy
21,265
+12,857
+153% +$754K 0.57% 48
2015
Q4
$552K Buy
+8,408
New +$520K 0.29% 98

Other funds holding TEVA

Laurel Wealth Advisors (California)'s TEVA Position: Q3 2017 in Review

Laurel Wealth Advisors (California) sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2017, closing a stake of 14,490 shares — an estimated $481K sold.

Laurel Wealth Advisors (California) first reported a position in TEVA in Q4 2015 and held it in 7 quarters. The position peaked at $1.24M in Q2 2016. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Laurel Wealth Advisors (California) reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2017 after selling out during the quarter.
  • Laurel Wealth Advisors (California) sold 14,490 Teva Pharmaceutical Industries Limited shares in Q3 2017, an estimated $481K.
  • Laurel Wealth Advisors (California) first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 7 quarters.
  • Laurel Wealth Advisors (California)'s Teva Pharmaceutical Industries Limited position peaked at $1.24M in Q2 2016.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2017.

Based on Laurel Wealth Advisors (California)'s 13F filing for Q3 2017, filed 14 Nov 2017.